Section of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The University of Oklahoma College of Medicine, Oklahoma City, OK.
Section of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The University of Oklahoma College of Medicine, Oklahoma City, OK; Department of Biostatistics and Epidemiology, Hudson College of Public Health, The University of Oklahoma Health Science Center, Oklahoma City, OK.
Am J Obstet Gynecol MFM. 2022 Sep;4(5):100681. doi: 10.1016/j.ajogmf.2022.100681. Epub 2022 Jun 18.
Women with obesity are at increased risk of complications during and after labor and delivery, including puerperal infection and cesarean delivery. As labor induction has become increasingly common, it is crucial to find ways to decrease complication rates in this high-risk population.
This study aimed to explore the effect of prophylactic antibiotics during labor induction of nulliparous women with obesity on the rates of cesarean delivery and puerperal infection and to estimate the parameters needed to calculate the sample size for a larger, multicenter trial.
In this randomized, placebo-controlled pilot trial, nulliparous patients with a body mass index of ≥30 kg/m were randomized to either prophylactic antibiotics (500 mg azithromycin for 1 dose and 2 g cefazolin every 8 hours for up to 3 doses) or placebo, administered starting at the beginning of labor induction. The exclusion criteria were known fetal anomaly, fetal demise, multifetal gestation, ruptured membranes >12 hours, infection requiring antibiotics at the start of labor induction, and/or allergy to azithromycin or beta-lactam antibiotics. The co-primary outcomes were rates of puerperal infection (composite of chorioamnionitis, endometritis, and/or cesarean delivery wound infection) and cesarean delivery. Participants were followed up for 30 days after delivery, and maternal and neonatal demographic and outcome data were collected. Proportions and 95% confidence limits were calculated for each of these outcomes.
From January 2019 to May 2021, 101 patients were randomized in the class III stratum (1 patient who was randomized ultimately did not undergo labor induction). From February 2020 to May 2021, 38 and 47 patients were randomized to class I and II strata, respectively (to assess the effect of obesity class on the outcomes expected to be influenced by antibiotic prophylaxis). In the antibiotics and placebo groups, the rates of cesarean delivery were 29.0% (95% confidence interval, 19.8-38.3) and 39.8% (95% confidence interval, 29.8-49.7), respectively, and puerperal infection occurred in 8.6% (95% confidence interval, 2.9-14.3) and 9.7% (95% confidence interval, 3.7-15.7), respectively. In the subgroup with class III obesity, in the antibiotics and placebo groups, the rates of cesarean delivery were 33.3% (95% confidence interval, 20.4-47.9) and 46.0% (95% confidence interval, 32.2-59.8), respectively, and puerperal infection occurred in 7.8% (95% confidence interval, 0.5-15.2) and 10.0% (95% confidence interval, 1.7-18.3), respectively. Note that this pilot study was not powered to detect differences of this magnitude but rather to estimate parameters.
The administration of prophylactic antibiotics during labor induction of nulliparous patients with obesity resulted in a 27% lower cesarean delivery rate overall and a 28% lower rate in patients with class III obesity. A larger trial is warranted to evaluate these differences.
肥胖女性在分娩和分娩期间及之后发生并发症的风险增加,包括产褥感染和剖宫产。由于引产越来越普遍,因此必须找到方法来降低高危人群的并发症发生率。
本研究旨在探讨对肥胖初产妇在引产时使用预防性抗生素对剖宫产率和产褥感染率的影响,并估计需要计算更大规模、多中心试验样本量的参数。
在这项随机、安慰剂对照的初步试验中,将 BMI≥30kg/m2 的初产妇随机分为预防性抗生素组(500mg 阿奇霉素单次剂量和 2g 头孢唑啉每 8 小时一次,最多 3 剂)或安慰剂组,从引产开始时给药。排除标准为已知胎儿异常、胎儿死亡、多胎妊娠、胎膜破裂>12 小时、引产时需要使用抗生素的感染、/或对阿奇霉素或β-内酰胺类抗生素过敏。主要复合结局为产褥感染(包括绒毛膜炎、子宫内膜炎和/或剖宫产伤口感染)和剖宫产率。对产妇和新生儿的人口统计学和结局数据进行了 30 天的随访。对每个结局计算了比例和 95%置信区间。
2019 年 1 月至 2021 年 5 月,101 名患者在 III 类分层中随机分组(1 名随机患者最终未接受引产)。2020 年 2 月至 2021 年 5 月,分别有 38 名和 47 名患者随机分为 I 类和 II 类分层(以评估肥胖程度对预计受抗生素预防影响的结局的影响)。在抗生素组和安慰剂组中,剖宫产率分别为 29.0%(95%置信区间,19.8-38.3)和 39.8%(95%置信区间,29.8-49.7),产褥感染发生率分别为 8.6%(95%置信区间,2.9-14.3)和 9.7%(95%置信区间,3.7-15.7)。在 III 类肥胖亚组中,在抗生素组和安慰剂组中,剖宫产率分别为 33.3%(95%置信区间,20.4-47.9)和 46.0%(95%置信区间,32.2-59.8),产褥感染发生率分别为 7.8%(95%置信区间,0.5-15.2)和 10.0%(95%置信区间,1.7-18.3)。需要注意的是,本初步研究没有足够的效力来检测到这种程度的差异,而是旨在估计参数。
对肥胖初产妇在引产时使用预防性抗生素可使总体剖宫产率降低 27%,III 类肥胖患者的剖宫产率降低 28%。需要进行更大规模的试验来评估这些差异。